August 5, 2020 -- Kriya Therapeutics has secured a 51,000-sq-ft facility in Research Triangle Park, NC, to establish internal operational manufacturing of its pipeline of adeno-associated virus (AAV)-based gene therapies.
The facility will be fully integrated with a process development lab, quality control and analytical development capabilities, pilot production suite, and current good manufacturing practice (cGMP) production infrastructure. A 2,000-L bioreactor will be used to manufacture gene therapies using a scalable suspension cell culture manufacturing process.
The pilot production suite is set to be online in the first half of 2021 and the full cGMP production facility is set to be online in the second half of 2021.
Copyright © 2020 scienceboard.net